Pharma & Biopharma Manufacturing
Asymchem Achieves First USFDA Inspection Milestone for Carbapenem API Manufacturing Facility
Asymchem, a leading global contract development and manufacturing organization (CDMO), announced that its dedicated carbapenem API manufacturing facil...
July 28, 2026 | News
7 Countries Competing to Be the Region’s Next Biomanufacturing Hub
A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...
July 27, 2026 | Analysis
Nova Biomedical Expands Cell Line Development Portfolio with NanoCellect Technology Acquisition
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
July 27, 2026 | News
The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028
There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...
July 24, 2026 | Analysis
Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303
Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...
July 24, 2026 | News
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 22, 2026 | News
Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...
July 21, 2026 | News
From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing
ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...
July 17, 2026 | Expert Insight
Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...
July 17, 2026 | News
China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?
THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...
July 16, 2026 | Analysis
ACROBiosystems Secures Japan PMDA Confirmation for GMP-Grade IL-15 Used in Cell Therapy Manufacturing
ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号...
July 16, 2026 | News
Insilico Medicine, Bora Pharmaceuticals Forge $2.5B Alliance to Build AI-Driven Drug Innovation Model
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generat...
July 16, 2026 | News
The Technology Is Ready. Are APAC’s Regulators?
In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...
July 15, 2026 | Regulatory
Takeda Backs Indonesia's Plasma Ambitions with US$30 Million Investment to Build ASEAN's First Integrated Plasma Ecosystem
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi...
July 14, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
